<!DOCTYPE html><html lang="en"><head><title>Static News</title><meta charSet="utf-8"/><meta name="description" content="Static delayed Hacker News."/><meta name="theme-color" media="(prefers-color-scheme: light)" content="white"/><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1d1f21"/><meta name="viewport" content="width=device-width,initial-scale=1.0"/><meta name="application-name" content="Static News"/><meta name="apple-mobile-web-app-title" content="Static News"/><meta name="apple-mobile-web-app-capable" content="yes"/><meta name="mobile-web-app-capable" content="yes"/><meta name="apple-mobile-web-app-status-bar-style" content="#1d1f21"/><link rel="preload" href="styles.css?v=1697619672475" as="style"/><link rel="stylesheet" href="styles.css?v=1697619672475"/></head><body><div id="container"><div id="inner"><header><a href="/">Static News</a><a href="/about">about</a></header><div id="content"><div><div id="title"><a href="https://ultimovacs.com/investors/news/ultimovacs-announces-nipu-results-presented-at-esmo-2023-significant-and-clinically-meaningful-improvement-in-overall-survival-for-patients-receiving-uv1-cancer-vaccine-in-phase-ii-nipu-trial-in-mali">Universal cancer vaccine trial shows significant improvement in overall survival</a> <span class="domain">(<a href="https://ultimovacs.com">ultimovacs.com</a>)</span></div><div class="subtext"><span>espenwa</span> | <span>33 comments</span></div><br/><div><div id="37923585" class="c"><input type="checkbox" id="c-37923585" checked=""/><div class="controls bullet"><span class="by">jseliger</span><span>|</span><a href="#37925938">next</a><span>|</span><label class="collapse" for="c-37923585">[-]</label><label class="expand" for="c-37923585">[15 more]</label></div><br/><div class="children"><div class="content">This is obviously good but note that it appears to be covering mesothelioma only, and &quot;The median [overall survival] OS was 15.4 months (95% CI, 11.1-22.6) for UV1 plus ipilimumab and nivolumab (treatment arm) versus 11.1 months (95% CI, 8.8-18.1) for ipilimumab and nivolumab alone.&quot; Another headline could be: &quot;Cancer vaccine helps some mesothelioma patients live an extra 4.3 months,&quot; which is less exciting than the headline&#x27;s current phrasing. It&#x27;s like how people are horrified by &quot;you have a 20% chance of dying&quot; but somewhat reassured by &quot;you have an 80% chance of living.&quot;<p>I&#x27;m dying from squamous cell carcinoma and am more excited about the Moderna approach with personalized cancer vaccines, like mRNA-4157. Early data for what I have is promising: <a href="https:&#x2F;&#x2F;www.fiercebiotech.com&#x2F;biotech&#x2F;moderna-s-keytruda-combo-misses-colorectal-cancer-as-it-shows-promise-head-and-neck" rel="nofollow noreferrer">https:&#x2F;&#x2F;www.fiercebiotech.com&#x2F;biotech&#x2F;moderna-s-keytruda-com...</a>: &quot;The combination treatment shrank tumors in five patients with head and neck cancer (50%), eliminating the tumors in two of those patients, Moderna said in a statement. Another four patients in that group had stable disease, meaning their tumors had stopped growing.&quot; Recurrent&#x2F;metastatic head and neck squamous cell carcinoma is almost always fatal: <a href="https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC8155962&#x2F;" rel="nofollow noreferrer">https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC8155962&#x2F;</a>, unless the person responds to pembrolizumab&#x2F;Keytruda (which I do not; about 20 - 30% of patients appear to respond, based on KEYNOTE-048: <a href="https:&#x2F;&#x2F;ascopubs.org&#x2F;doi&#x2F;full&#x2F;10.1200&#x2F;JCO.21.02508" rel="nofollow noreferrer">https:&#x2F;&#x2F;ascopubs.org&#x2F;doi&#x2F;full&#x2F;10.1200&#x2F;JCO.21.02508</a>). Unfortunately, Moderna won&#x27;t make mRNA-4157 available under compassionate use or through any other means. :(<p>Moderna, however, is in a Phase III study of mRNA-4157 in melanoma: <a href="https:&#x2F;&#x2F;www.onclive.com&#x2F;view&#x2F;adjuvant-mrna-4157-plus-pembrolizumab-improves-rfs-in-resected-high-risk-melanoma" rel="nofollow noreferrer">https:&#x2F;&#x2F;www.onclive.com&#x2F;view&#x2F;adjuvant-mrna-4157-plus-pembrol...</a>. Given the miraculous early data for R&#x2F;M HNSCC, one hopes they&#x27;ll launch new trials.<p>Nivolumab is a PD-1 inhibitor, like pembrolizumab&#x2F;Keytruda, but I don&#x27;t know anything more about it.</div><br/><div id="37924626" class="c"><input type="checkbox" id="c-37924626" checked=""/><div class="controls bullet"><span class="by">nextos</span><span>|</span><a href="#37923585">parent</a><span>|</span><a href="#37925231">next</a><span>|</span><label class="collapse" for="c-37924626">[-]</label><label class="expand" for="c-37924626">[1 more]</label></div><br/><div class="children"><div class="content">&gt; Unfortunately, Moderna won&#x27;t make mRNA-4157 available under compassionate use<p>Sorry to hear. Try contacting Immunocore in Oxford, they have a TCR therapy that targets many tumors, including squamous ones, and they are recruiting or should make it available under compassionate use. Other companies worth looking into are Adaptimmune Therapeutics, also in Oxford, and Evaxion in Copenhagen. They are all going the semi-personalized route. So will look into your tumor type, MHC class I, etc.</div><br/></div></div><div id="37925231" class="c"><input type="checkbox" id="c-37925231" checked=""/><div class="controls bullet"><span class="by">henry2023</span><span>|</span><a href="#37923585">parent</a><span>|</span><a href="#37924626">prev</a><span>|</span><a href="#37923840">next</a><span>|</span><label class="collapse" for="c-37925231">[-]</label><label class="expand" for="c-37925231">[1 more]</label></div><br/><div class="children"><div class="content">I&#x27;m sorry to hear that. I have zero knowledge about your specific condition and I hope the best for you. Given that, I want to recommend you to read Being Mortal by Atul Gawande. It&#x27;s rough, anti status-quo, and yet very compelling.</div><br/></div></div><div id="37923840" class="c"><input type="checkbox" id="c-37923840" checked=""/><div class="controls bullet"><span class="by">huytersd</span><span>|</span><a href="#37923585">parent</a><span>|</span><a href="#37925231">prev</a><span>|</span><a href="#37924145">next</a><span>|</span><label class="collapse" for="c-37923840">[-]</label><label class="expand" for="c-37923840">[4 more]</label></div><br/><div class="children"><div class="content">Weren’t you able to get into the study at UCSD? How is that going? Are you allowed to talk about it?</div><br/><div id="37924671" class="c"><input type="checkbox" id="c-37924671" checked=""/><div class="controls bullet"><span class="by">jseliger</span><span>|</span><a href="#37923585">root</a><span>|</span><a href="#37923840">parent</a><span>|</span><a href="#37924145">next</a><span>|</span><label class="collapse" for="c-37924671">[-]</label><label class="expand" for="c-37924671">[3 more]</label></div><br/><div class="children"><div class="content">I was! I&#x27;ve now been infused twice with 1100mg of petosemtamab &#x2F; MCLA-158 (<a href="https:&#x2F;&#x2F;beta.clinicaltrials.gov&#x2F;study&#x2F;NCT03526835" rel="nofollow noreferrer">https:&#x2F;&#x2F;beta.clinicaltrials.gov&#x2F;study&#x2F;NCT03526835</a>), on Sept. 27 and then Oct. 12. The next is Oct. 25. For the first week I had no apparent reactions, and then a rash erupted on my face, chest, and back. That&#x27;s pretty normal for EGFR drugs, and the rash was (and is) itchy and annoying but not unbearable. To treat it, I inject an antibiotic called doxycycline (which is used against acne bacteria) into my peg tube and use a a topical steroid. At the bottom of this post: <a href="https:&#x2F;&#x2F;jakeseliger.com&#x2F;2023&#x2F;10&#x2F;16&#x2F;how-do-you-say-goodbye&#x2F;" rel="nofollow noreferrer">https:&#x2F;&#x2F;jakeseliger.com&#x2F;2023&#x2F;10&#x2F;16&#x2F;how-do-you-say-goodbye&#x2F;</a> there&#x27;s a photo showing some of what&#x27;s happening to my face.<p>So, overall it&#x27;s going pretty well, and I feel physically better than I did on chemo and Keytruda—a low bar, but I&#x27;ll take whatever improvements I can get. The next CT scans are scheduled for Nov. 21, but unless I&#x27;m responding to petosemtamab in a pretty major way, they&#x27;ll probably be ambiguous. The median time to respond is 1.8 months, so it&#x27;d be surprising to see big changes between the Sept. 5 CT baseline CT scans and the Nov. 21 scans. Two tumors are physically protruding from my neck, which is disconcerting, but they aren&#x27;t painful.<p>The FDA apparently wants to see how the 1100mg and 1500mg petosemtamab doses differ, and I got randomized to the lower dose. That isn&#x27;t necessarily bad: more of a drug can be deleterious relative to right dose.<p>I wasn&#x27;t NDA&#x27;ed, so I&#x27;m assuming I can talk about what&#x27;s going on. I&#x27;m a bit surprised by the lack of an NDA; I&#x27;ve signed NDAs for three-person startups who want grant writing services for a Dept. of Energy Small Business Innovation and Research (SBIR) proposal, but nothing WRT this.</div><br/><div id="37924992" class="c"><input type="checkbox" id="c-37924992" checked=""/><div class="controls bullet"><span class="by">NetOpWibby</span><span>|</span><a href="#37923585">root</a><span>|</span><a href="#37924671">parent</a><span>|</span><a href="#37924800">next</a><span>|</span><label class="collapse" for="c-37924992">[-]</label><label class="expand" for="c-37924992">[1 more]</label></div><br/><div class="children"><div class="content">Thank you for sharing and I hope the science evolves alongside your recovery.</div><br/></div></div><div id="37924800" class="c"><input type="checkbox" id="c-37924800" checked=""/><div class="controls bullet"><span class="by">huytersd</span><span>|</span><a href="#37923585">root</a><span>|</span><a href="#37924671">parent</a><span>|</span><a href="#37924992">prev</a><span>|</span><a href="#37924145">next</a><span>|</span><label class="collapse" for="c-37924800">[-]</label><label class="expand" for="c-37924800">[1 more]</label></div><br/><div class="children"><div class="content">Thanks for the update and I hope this works out.</div><br/></div></div></div></div></div></div><div id="37924145" class="c"><input type="checkbox" id="c-37924145" checked=""/><div class="controls bullet"><span class="by">btilly</span><span>|</span><a href="#37923585">parent</a><span>|</span><a href="#37923840">prev</a><span>|</span><a href="#37923722">next</a><span>|</span><label class="collapse" for="c-37924145">[-]</label><label class="expand" for="c-37924145">[4 more]</label></div><br/><div class="children"><div class="content">Do you have an opinion on <a href="https:&#x2F;&#x2F;www.science.org&#x2F;content&#x2F;blog-post&#x2F;new-mode-cancer-treatment" rel="nofollow noreferrer">https:&#x2F;&#x2F;www.science.org&#x2F;content&#x2F;blog-post&#x2F;new-mode-cancer-tr...</a>?</div><br/><div id="37924736" class="c"><input type="checkbox" id="c-37924736" checked=""/><div class="controls bullet"><span class="by">jseliger</span><span>|</span><a href="#37923585">root</a><span>|</span><a href="#37924145">parent</a><span>|</span><a href="#37924768">next</a><span>|</span><label class="collapse" for="c-37924736">[-]</label><label class="expand" for="c-37924736">[1 more]</label></div><br/><div class="children"><div class="content">Nope. Nothing other than &quot;I hope it works!&quot; Interestingly, AOH1996 is supposed to be given at Honor Health Research Institute: <a href="https:&#x2F;&#x2F;beta.clinicaltrials.gov&#x2F;study&#x2F;NCT05227326" rel="nofollow noreferrer">https:&#x2F;&#x2F;beta.clinicaltrials.gov&#x2F;study&#x2F;NCT05227326</a>, which is down the street from me, but the trial isn&#x27;t listed as recruiting yet. Not sure why: if I weren&#x27;t in the trial I&#x27;m in (<a href="https:&#x2F;&#x2F;news.ycombinator.com&#x2F;item?id=37924671">https:&#x2F;&#x2F;news.ycombinator.com&#x2F;item?id=37924671</a>), AOH1996 would likely be on the list. It&#x27;s a first-in-human trial with only 8 participants, and most drugs, even super promising-seeming ones, don&#x27;t make it even to phase 2.<p>But <a href="https:&#x2F;&#x2F;www.clinicaltrials.gov&#x2F;study&#x2F;NCT04787042" rel="nofollow noreferrer">https:&#x2F;&#x2F;www.clinicaltrials.gov&#x2F;study&#x2F;NCT04787042</a> is also a promising phase 1 trial for an interleukin-18 attack, and it&#x27;s also at Honor Health.</div><br/></div></div><div id="37924768" class="c"><input type="checkbox" id="c-37924768" checked=""/><div class="controls bullet"><span class="by">ramraj07</span><span>|</span><a href="#37923585">root</a><span>|</span><a href="#37924145">parent</a><span>|</span><a href="#37924736">prev</a><span>|</span><a href="#37925429">next</a><span>|</span><label class="collapse" for="c-37924768">[-]</label><label class="expand" for="c-37924768">[1 more]</label></div><br/><div class="children"><div class="content">Not who you asked but that’s a promising molecule. Unfortunately until we see phase 1&#x2F;2 results we can’t be sure if it ends up actually being effective. It’s sad that we can’t predict efficacy any better without injecting actual people with the drug but that’s reality. Cancer is too complex to model any other way in a complete fashion.  If a drug is blockbuster effective you’d notice in phase 1 itself, as was the case for ibrutinib. Fingers crossed.</div><br/></div></div><div id="37925429" class="c"><input type="checkbox" id="c-37925429" checked=""/><div class="controls bullet"><span class="by">adamredwoods</span><span>|</span><a href="#37923585">root</a><span>|</span><a href="#37924145">parent</a><span>|</span><a href="#37924768">prev</a><span>|</span><a href="#37923722">next</a><span>|</span><label class="collapse" for="c-37925429">[-]</label><label class="expand" for="c-37925429">[1 more]</label></div><br/><div class="children"><div class="content">In my air-chair opinion, the future of cancer treatments will not be one &quot;cure-all&quot; drug, but many, all depending on a cancer&#x27;s characteristics and an individual&#x27;s response to treatments. Cancer can also mutate or become metastatic when under duress, so the characteristics change then as well.<p>So the more treatments we can create, the better.</div><br/></div></div></div></div><div id="37923722" class="c"><input type="checkbox" id="c-37923722" checked=""/><div class="controls bullet"><span class="by">criley2</span><span>|</span><a href="#37923585">parent</a><span>|</span><a href="#37924145">prev</a><span>|</span><a href="#37924478">next</a><span>|</span><label class="collapse" for="c-37923722">[-]</label><label class="expand" for="c-37923722">[2 more]</label></div><br/><div class="children"><div class="content">&quot;Phase II studies are ongoing in patients with malignant melanoma, head and neck cancer, ovarian cancer, and non-small cell lung cancer.&quot;</div><br/><div id="37924673" class="c"><input type="checkbox" id="c-37924673" checked=""/><div class="controls bullet"><span class="by">jseliger</span><span>|</span><a href="#37923585">root</a><span>|</span><a href="#37923722">parent</a><span>|</span><a href="#37924478">next</a><span>|</span><label class="collapse" for="c-37924673">[-]</label><label class="expand" for="c-37924673">[1 more]</label></div><br/><div class="children"><div class="content">Thank you! I missed that sentence. Embarrassing. Will be interested to see how it performs.</div><br/></div></div></div></div><div id="37925879" class="c"><input type="checkbox" id="c-37925879" checked=""/><div class="controls bullet"><span class="by">NotGMan</span><span>|</span><a href="#37923585">parent</a><span>|</span><a href="#37924478">prev</a><span>|</span><a href="#37925938">next</a><span>|</span><label class="collapse" for="c-37925879">[-]</label><label class="expand" for="c-37925879">[1 more]</label></div><br/><div class="children"><div class="content">There are cases when certain cancers at least stopped progressing or were healed by a combination of low carb diet + cyclical water fasting.<p>Eg low carb ~3 weeks, 1 week water fast cycles.<p>Some people even did 30 day water fasts and the cancer dissapeared.<p>Some cancers respond well to a low carb diet, others don&#x27;t.<p>This is what I&#x27;d do if I&#x27;d had cancer.<p>Some links, you can find more on google&#x2F;youtube (do note that youtube is heavily censoring low carb stuff since &quot;it&#x27;s not mainstream approved&quot; lol despite people healing conditions on it that no modern medicine could).<p><a href="https:&#x2F;&#x2F;www.youtube.com&#x2F;watch?v=Rhs1BB7MbHo">https:&#x2F;&#x2F;www.youtube.com&#x2F;watch?v=Rhs1BB7MbHo</a>   (at 1:03:20)<p>Another one:
How my Immune System beat cancer: Fasting, Juicing, Ketogenic diet, Breathing, Exercise, Meditation and other non-toxic therapies Paperback – January 12, 2021
by Fred Evrard<p><a href="https:&#x2F;&#x2F;www.youtube.com&#x2F;@CancerTherapy&#x2F;videos">https:&#x2F;&#x2F;www.youtube.com&#x2F;@CancerTherapy&#x2F;videos</a><p><a href="https:&#x2F;&#x2F;www.youtube.com&#x2F;watch?v=WJQn6WZGAQ0">https:&#x2F;&#x2F;www.youtube.com&#x2F;watch?v=WJQn6WZGAQ0</a><p><a href="https:&#x2F;&#x2F;www.youtube.com&#x2F;watch?v=jK0BkTPUGQY">https:&#x2F;&#x2F;www.youtube.com&#x2F;watch?v=jK0BkTPUGQY</a></div><br/></div></div></div></div><div id="37925938" class="c"><input type="checkbox" id="c-37925938" checked=""/><div class="controls bullet"><span class="by">jorgtron</span><span>|</span><a href="#37923585">prev</a><span>|</span><a href="#37923701">next</a><span>|</span><label class="collapse" for="c-37925938">[-]</label><label class="expand" for="c-37925938">[1 more]</label></div><br/><div class="children"><div class="content">Note that this is for a very hard cancer to treat, and no one was expecting the great results seen here. Upcoming studies will focus on other cancer types where we expect results to be even better.<p>Disclaimer: I&#x27;m an investor in Ultimovacs and run a community for Ultimovacs investors at tekinvestor.no (in Norwegian, but google translate can help :))<p>&quot;Ultimovacs is evaluating the universal cancer vaccine UV1 in a broad clinical development program across various cancer indications with different biologies and disease stages, in combination with different checkpoint inhibitors. The topline data from NIPU are the first results among the five randomized trials in the UV1 Phase II clinical program. In addition to malignant mesothelioma, Phase II studies are ongoing in patients with malignant melanoma, head and neck cancer, ovarian cancer, and non-small cell lung cancer. The topline data from the malignant melanoma and head and neck cancer trials are expected during the first and second half of 2024. UV1 is a patented, proprietary technology owned by Ultimovacs.&quot;</div><br/></div></div><div id="37923701" class="c"><input type="checkbox" id="c-37923701" checked=""/><div class="controls bullet"><span class="by">berbec</span><span>|</span><a href="#37925938">prev</a><span>|</span><a href="#37924554">next</a><span>|</span><label class="collapse" for="c-37923701">[-]</label><label class="expand" for="c-37923701">[5 more]</label></div><br/><div class="children"><div class="content">I have a friend doing her PhD in cancer research. She tells me to take every Phase I trial with a huge grain of salt, because they rarely make it to market. [1]<p>1: <a href="https:&#x2F;&#x2F;i.postimg.cc&#x2F;L4G0FdWf&#x2F;cancer-study.jpg" rel="nofollow noreferrer">https:&#x2F;&#x2F;i.postimg.cc&#x2F;L4G0FdWf&#x2F;cancer-study.jpg</a></div><br/><div id="37926100" class="c"><input type="checkbox" id="c-37926100" checked=""/><div class="controls bullet"><span class="by">Neil44</span><span>|</span><a href="#37923701">parent</a><span>|</span><a href="#37923731">next</a><span>|</span><label class="collapse" for="c-37926100">[-]</label><label class="expand" for="c-37926100">[1 more]</label></div><br/><div class="children"><div class="content">It&#x27;s part of the huge, finger in the air balancing act of developing drugs. How much money do you put into early phase 1 and before stuff that may or may not make it. And what&#x27;s the market if it does make it. Because the ones that do make it have to cover the cost of all the ones that don&#x27;t, who&#x27;s learning it took to get to this point.</div><br/></div></div><div id="37923731" class="c"><input type="checkbox" id="c-37923731" checked=""/><div class="controls bullet"><span class="by">criley2</span><span>|</span><a href="#37923701">parent</a><span>|</span><a href="#37926100">prev</a><span>|</span><a href="#37923937">next</a><span>|</span><label class="collapse" for="c-37923731">[-]</label><label class="expand" for="c-37923731">[2 more]</label></div><br/><div class="children"><div class="content">These are Phase II trials.</div><br/><div id="37924771" class="c"><input type="checkbox" id="c-37924771" checked=""/><div class="controls bullet"><span class="by">ramraj07</span><span>|</span><a href="#37923701">root</a><span>|</span><a href="#37923731">parent</a><span>|</span><a href="#37923937">next</a><span>|</span><label class="collapse" for="c-37924771">[-]</label><label class="expand" for="c-37924771">[1 more]</label></div><br/><div class="children"><div class="content">There’s a lot of approved cancer treatment protocols that increase median survival by a mere few weeks. This drug also seems to be heading that way.</div><br/></div></div></div></div><div id="37923937" class="c"><input type="checkbox" id="c-37923937" checked=""/><div class="controls bullet"><span class="by">extraduder_ire</span><span>|</span><a href="#37923701">parent</a><span>|</span><a href="#37923731">prev</a><span>|</span><a href="#37924554">next</a><span>|</span><label class="collapse" for="c-37923937">[-]</label><label class="expand" for="c-37923937">[1 more]</label></div><br/><div class="children"><div class="content">Is this image from something with stats? The numbers seem kind of round.<p>Not that specific stats would help me that much.</div><br/></div></div></div></div><div id="37924554" class="c"><input type="checkbox" id="c-37924554" checked=""/><div class="controls bullet"><span class="by">m3kw9</span><span>|</span><a href="#37923701">prev</a><span>|</span><a href="#37925388">next</a><span>|</span><label class="collapse" for="c-37924554">[-]</label><label class="expand" for="c-37924554">[7 more]</label></div><br/><div class="children"><div class="content">27% doesn’t seem all that significant considering a vaccine</div><br/><div id="37925356" class="c"><input type="checkbox" id="c-37925356" checked=""/><div class="controls bullet"><span class="by">adamredwoods</span><span>|</span><a href="#37924554">parent</a><span>|</span><a href="#37924639">next</a><span>|</span><label class="collapse" for="c-37925356">[-]</label><label class="expand" for="c-37925356">[1 more]</label></div><br/><div class="children"><div class="content">Pretty good numbers, actually, considering the other conventional treatments for mesothelioma (surgery, aggressive chemo) is similar:<p>&gt;&gt; The median survival for patients in the chemotherapy arms was 8.5 months compared to 7.6 months for BSC (best supportive care), which was not statistically different.<p><a href="https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC3307510&#x2F;" rel="nofollow noreferrer">https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC3307510&#x2F;</a></div><br/></div></div><div id="37924639" class="c"><input type="checkbox" id="c-37924639" checked=""/><div class="controls bullet"><span class="by">brokensegue</span><span>|</span><a href="#37924554">parent</a><span>|</span><a href="#37925356">prev</a><span>|</span><a href="#37925388">next</a><span>|</span><label class="collapse" for="c-37924639">[-]</label><label class="expand" for="c-37924639">[5 more]</label></div><br/><div class="children"><div class="content">&gt;A 2021 study showed that among adults hospitalized with flu, vaccinated patients had a 26% lower risk of intensive care unit (ICU) admission and a 31% lower risk of death from flu compared with those who were unvaccinated.<p>Yet you should still be getting the flu vaccine</div><br/><div id="37924819" class="c"><input type="checkbox" id="c-37924819" checked=""/><div class="controls bullet"><span class="by">somenameforme</span><span>|</span><a href="#37924554">root</a><span>|</span><a href="#37924639">parent</a><span>|</span><a href="#37925388">next</a><span>|</span><label class="collapse" for="c-37924819">[-]</label><label class="expand" for="c-37924819">[4 more]</label></div><br/><div class="children"><div class="content">Numbers like that are highly misleading, because it&#x27;s a conditional. If your chances of dying from something are 1 in 10 million, and a treatment changes that to 1 in a billion, then that treatment would mean you&#x27;re 99% less likely to die of whatever. But the risk of death is so extremely low to begin with, that that 99% figure is largely just noise.<p>I mean noise in both the colloquial sense, as well as the statistical one. It&#x27;s difficult to measure the effectiveness of treatments when what you&#x27;re treating is so relatively harmless. An experimental study, outside of an absurd size, would show 0 deaths. So you only have observational studies left, which tend to be deeply flawed and <i>highly</i> susceptible to number juking.<p>In any case, if somebody dies from the flu they were likely quite elderly, or had severe preexisting conditions. And so it&#x27;s this group of people that taking things like a flus hot can make the most sense. But if you take e.g. a younger to mid aged person of good health, his chance of dying from the flu are practically zero. If they want to get it, more power to them. But saying all people <i>should</i> get a flu shot, does not seem to make much sense.</div><br/><div id="37924912" class="c"><input type="checkbox" id="c-37924912" checked=""/><div class="controls bullet"><span class="by">brokensegue</span><span>|</span><a href="#37924554">root</a><span>|</span><a href="#37924819">parent</a><span>|</span><a href="#37925388">next</a><span>|</span><label class="collapse" for="c-37924912">[-]</label><label class="expand" for="c-37924912">[3 more]</label></div><br/><div class="children"><div class="content">The flu vaccine reduces severity and likelihood of catching it as well (which can serve to protect vulnerable populations). Your own personal chance of death is not all that matters.<p>Getting it yearly may also reduce the risk of other related conditions e.g. <a href="https:&#x2F;&#x2F;www.uth.edu&#x2F;news&#x2F;story&#x2F;uthealth-houston-study-flu-vaccination-linked-to-40-reduced-risk-of-alzheimers-disease" rel="nofollow noreferrer">https:&#x2F;&#x2F;www.uth.edu&#x2F;news&#x2F;story&#x2F;uthealth-houston-study-flu-va...</a><p>It&#x27;s nearly risk free and it&#x27;s definitely worth it even if all it did was decrease the severity of flu if you catch it (and it does more than that).</div><br/><div id="37925283" class="c"><input type="checkbox" id="c-37925283" checked=""/><div class="controls bullet"><span class="by">somenameforme</span><span>|</span><a href="#37924554">root</a><span>|</span><a href="#37924912">parent</a><span>|</span><a href="#37925388">next</a><span>|</span><label class="collapse" for="c-37925283">[-]</label><label class="expand" for="c-37925283">[2 more]</label></div><br/><div class="children"><div class="content">The flu shot does not prevent one from getting the flu and spreading it to others. Like the past 3 years have shown, you&#x27;re just not going to get herd immunity with these short term low efficacy shots, even when paired alongside monumental, wide scale, and completely unsustainable efforts.<p>Also, the risk of something needs to be put in context of the risk of what you&#x27;re protecting against. If something only has a severe negative side effect 1 in a million times, then it absolutely should be considered extremely low risk. But you&#x27;re risk of whatever it&#x27;s protecting against only has a severe outcome 1 in 2 million times? Well not only should it <i>also</i> then be considered extremely low risk, but getting the treatment would be quite illogical. These risks also needs to be multiplied repeatedly for low efficacy treatments which entail annual use.</div><br/><div id="37925698" class="c"><input type="checkbox" id="c-37925698" checked=""/><div class="controls bullet"><span class="by">haldujai</span><span>|</span><a href="#37924554">root</a><span>|</span><a href="#37925283">parent</a><span>|</span><a href="#37925388">next</a><span>|</span><label class="collapse" for="c-37925698">[-]</label><label class="expand" for="c-37925698">[1 more]</label></div><br/><div class="children"><div class="content">Both of your comments have described concepts that are very important to understand when discussing medical interventions, especially at the population level. Your reasoning is correct, I just wanted to add the terminology we use:<p>Absolute risk reduction (ARR), relative risk reduction (RRR), number needed to treat (NNT), number needed to harm (NNH).<p>Reading about these is a good starting point for anyone wanting to understand more about the decision making process.</div><br/></div></div></div></div></div></div></div></div></div></div></div></div><div id="37925388" class="c"><input type="checkbox" id="c-37925388" checked=""/><div class="controls bullet"><span class="by">andrewstuart</span><span>|</span><a href="#37924554">prev</a><span>|</span><a href="#37925101">next</a><span>|</span><label class="collapse" for="c-37925388">[-]</label><label class="expand" for="c-37925388">[1 more]</label></div><br/><div class="children"><div class="content">2035:<p>&quot;How are you feeling?&quot;<p>&quot;Oh, a touch of cancer last week but I popped a couple of pills and all good now&quot;.</div><br/></div></div><div id="37925101" class="c"><input type="checkbox" id="c-37925101" checked=""/><div class="controls bullet"><span class="by">cpncrunch</span><span>|</span><a href="#37925388">prev</a><span>|</span><a href="#37925432">next</a><span>|</span><label class="collapse" for="c-37925101">[-]</label><label class="expand" for="c-37925101">[1 more]</label></div><br/><div class="children"><div class="content">“the study did not meet the primary endpoint”</div><br/></div></div><div id="37925432" class="c"><input type="checkbox" id="c-37925432" checked=""/><div class="controls bullet"><span class="by">anovikov</span><span>|</span><a href="#37925101">prev</a><span>|</span><a href="#37924596">next</a><span>|</span><label class="collapse" for="c-37925432">[-]</label><label class="expand" for="c-37925432">[1 more]</label></div><br/><div class="children"><div class="content">This is officially the king of all clickbait</div><br/></div></div><div id="37924596" class="c"><input type="checkbox" id="c-37924596" checked=""/><div class="controls bullet"><span class="by">erickf1</span><span>|</span><a href="#37925432">prev</a><span>|</span><label class="collapse" for="c-37924596">[-]</label><label class="expand" for="c-37924596">[1 more]</label></div><br/><div class="children"><div class="content">Sounds like another money maker for the pharmaceutical industry that does nothing for the patient.</div><br/></div></div></div></div></div></div></div></body></html>